Partner with us in the fight against UM

The robust preclinical data obtained by the consortium should allow for biology-driven UM-specific clinical trials to be undertaken outside the framework of our project, as early as 2018. Together with our Scientific Advisory Board we will manage a pipeline of promising new therapeutic approaches for UM patients with metastatic disease, so we build strong and accurate preclinical packages. The potential availability of an active treatment for UM patients with metastases would ‘pave the way’ for future adjuvant treatments in UM patients with a high risk to develop disseminated disease.  

Please contact us if you’d like to know more and join us in the fight against Uveal Melanoma. 

Follow us